Complete Remission with Anti-CD20 Therapy for Unicentric, Non-HIV-Associated, Hyaline-Vascular Type, Castleman's Disease

Estephan, Fadi; Elghetany, M. Tarek; Berry, Madonna; Jones, Dennie V.

doi:10.1081/cnv-200050484

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical response was associated with a decrease in viral load. Rituximab has also been used successfully in other circumstances, such as in UCD [68], MCD associated with autoimmune phenomenon [69], and POEMS [70].…”

Section: Targeted Therapymentioning

confidence: 99%

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

2011

View full text Add to dashboard Cite

Castleman's disease is a rare lymphoproliferative disorder in which there has been recent progress in elucidating underlying mechanisms with potential therapeutic implications. Unicentric Castleman's disease is an indolent condition that is often treated with local approaches. In contrast, patients with multicentric Castleman's disease (MCD) have a less favorable prognosis and require systemic treatment. Cytotoxic chemotherapy, with its attendant risk for toxicity, has been widely used to treat MCD, with variable efficacy. The discovery of putative etiologic factors and targets in MCD, particularly human herpes virus 8, CD20, and interleukin (IL)-6, has been translated into the use of rituximab and anti-IL-6-based therapy, as well as antiviral agents. In this article, we review the current state of the art of our understanding of Castleman's disease and its treatment and we provide insight into future treatment strategies based on disease biology. The Oncologist 2011;16:497-511

show abstract

Section: Targeted Therapymentioning

confidence: 99%

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

2011

View full text Add to dashboard Cite

show abstract

“…Targeting and deleting CD20-positive B cells, a prominent component of Castleman's disease, is a new immunotherapeutic approach which is responsible for the deregulated productions of human IL-6, vascular endothelial growth factor (VEGF) and other cytokines as well. [5]…”

Section: Discussionmentioning

confidence: 99%

Persistent or recurrent Castleman′s disease - Look out for a lurking lymphoma!

Rao

Ramesh

Rajkumar

et al. 2011

Indian Journal of Medical and Paediatric Oncology

View full text Add to dashboard Cite

Castleman's disease, a rare condition of uncertain etiology clinically presents in isolated form or as a multicentric disease. The multicentric form can develop malignancies such as Kaposi's sarcoma or lymphomas. We present a case of Castleman's disease with coexisting interfollicular Hodgkin's lymphoma that was confirmed by immunohistochemistry. This case report highlights the fact that an occult lymphoma has to be ruled out in persistent or recurrent Castleman's disease.

show abstract

“…22 The plasma cell type has a low level of CT contrast enhancement. 23 MRI findings, including heterogeneous hypointensity on T 1 -weighted and hyperintensity on T 2 -weighted images, are non-specific. 21,22 None of the imaging findings is specific enough to establish the diagnosis definitively.…”

Section: Diagnosismentioning

confidence: 99%

“…There has been one report of complete remission of unicentric Castleman disease with anti-CD20 therapy, but surgical excision of unicentric tumours is believed to be the treatment of choice. 23 The number of reported cases is small, but it appears that complete resection is usually curative. Five series, including that of 95 patients, of hyaline vascular Castleman disease have been published, to which we can add our similar study 17 patients similar for a total of 112.…”

Section: Managementmentioning

confidence: 99%